As people age or become ill, their immune systems can become exhausted and less capable of fighting off viruses such as the flu or COVID-19.
Physicians forecast Edwards’ 5-year data will have limited impact on low-risk TAVR market
Dive Brief: Edwards Lifesciences’ upcoming five-year data on transcatheter aortic valve replacement (TAVR) for low-risk patients is unlikely to have a big effect on market
October 20, 2023